Korean J Vet Res > Volume 61(1); 2021 > Article
Choi, Nam, Kim, Park, Song, and Seo: Retrospective evaluation of toceranib phosphate (Palladia) for treatment of different tumor types in 31 dogs


The purpose of this retrospective study was to provide additional data on the use of toceranib in a wide variety of tumor types in small breed dogs, especially < 8 kg (except 5 dogs). This was a retrospective study of 31 dogs with malignant tumors treated with a 2.5 mg/kg median dose of toceranib (Palladia; Zoetis, USA) on a Monday-Wednesday-Friday schedule. Clinical benefit was observed in 13 of 15 dogs (86.7%, 3 with complete response, 4 with partial response, 6 with stable disease) with gross disease. Distant metastasis, response to treatment, and treatment setting were significantly associated with survival time. Negative prognostic factors were multiple chemotherapy and distant metastasis (affecting progression-free survival [PFS]), surgery, regional enlarged lymph nodes, underlying disease, and toxicity (affecting median survival time [MST]). Positive prognostic factors were epithelial and round cell tumor (affecting PFS), epithelial tumor, microscopic disease, no evidence of disease response, and stable disease (MST). In conclusion, a clinical benefit from toceranib treatment was noted in most of the dogs with gross disease in our study. This study suggested that the toceranib is probably selective treatment to various tumor types in small breed dogs.


Toceranib phosphate, a small molecule tyrosine kinase inhibitor, is commonly used in veterinary oncology. Receptor tyrosine kinases (RTKs) are good candidates for targeted molecular treatment as they play important roles in cell survival and proliferation and are dysregulated in a diverse range of malignancies through overexpression, activating mutations, and autocrine activation loops [1]. Toceranib inhibits both normal and mutated RTKs by competitive inhibition of adenosine triphosphate binding, which is need to phosphorylation and downstream signaling. The targets of toceranib are split-kinase family elements such as the FMS-like tyrosine kinase-3, KIT, vascular endothelial growth factor receptor 2, and platelet-derived growth factor receptor β, in a similar manner to sunitinib malate, another small-molecule inhibitor of RTKs [2,3]. Toceranib has not only antitumor but also antiangiogenic effects, and therefore has the potential to treat various tumor types [1,4-6].
Toceranib was approved by the Food and Drug Administration for the treatment of canine mast cell tumors (MCTs) in 2009. Its safety and activity were first assessed in a Phase 1 clinical trial involving a total of 57 dogs with a variety of tumors [5]. In this study, 31 dogs had an objective response (54.4%; 6 with complete response [CR], 10 with partial response [PR], and 15 with stable disease [SD]), demonstrating the potential biological activity of toceranib. The highest response rate was observed in 22 dogs with MCTs (59.1%, 13/22), including 11 dogs with KIT mutations (90.9%, 10/11) and sarcomas, carcinomas, melanomas, and myeloma also responded to the treatment [5]. Various reports have described the evaluation of toceranib [7,8]. Apart from MCTs [6,9], off-label uses have been described in a variety of tumors, including those of epithelial origin (apocrine gland anal sac adenocarcinoma [AGASA] [10,11], squamous cell carcinoma [SCC] [12], hepatocellular carcinoma [13], nasal carcinoma [11], thyroid carcinoma [14], and mammary gland tumor [15]), mesenchymal origin (osteosarcoma [OSA] [11,16,17], gastrointestinal stromal tumor [GIST] [18], and melanoma [5]), and round cell origin (lymphoma [19]). In one study that reported toceranib’s use in the treatment of solid tumors (AGASA, OSAs, thyroid carcinoma, and head and neck carcinoma), a clinical benefit was observed in 63/85 (74.1%) dogs [11].
Studies evaluated prognostic factors for the application of toceranib to general tumors were not enough and no cases were previously applied to majority of small breed dogs. Therefore, the purpose of the following retrospective study was to provide additional data on the use of toceranib in a wide variety of tumor types in small breed dogs, especially < 8 kg (except 5 dogs). This study describes the responses of toceranib treatment to various tumors, which has been reported for the first time in republic of Korea.

Materials and Methods

Case selection and treatment procedures

The client-owned dogs in this study were treated at the Veterinary Medical Teaching Hospital College of Chungnam National University or local referral veterinary clinics in Korea between January 2016 and September 2020. Medical charts with the owner’s consent to the use of patient information prior to medical care were used in this study. Authors declare no IACUC or other approval was needed for our study. We identified dogs that received diagnoses of malignant tumors by reviewing the medical records, from which we also recorded signalment (age, sex, and breed), physical examination, complete blood count (CBC), serum biochemistry profile, urinalysis, diagnostic imaging, histopathological assessment, toceranib dose and schedule (interval and duration), concomitant medications, and follow-up information including adverse events (AEs) and response to treatment. Lymph node (LN) assessment was performed in all patients through ultrasonography (US) and distant metastasis was evaluated by computed tomography (CT). In addition, the basal conditions of all patients were recorded before the treatment began. Dogs were excluded from the study (n = 7; 6 epithelial origin and 1 mesenchymal origin) if they were treated with toceranib for less than 28 days because it is difficult to assess the effects in short courses of treatment, as has been previously reported in solid tumors (except round cell populations) [1,16].
Re-evaluations, including physical examination, CBC, serum biochemistry, and urinalysis, were performed within a month of starting toceranib (usually within two weeks). Tumors were restaged based on direct measurement of gross mass or imaging (radiography, US, or CT) and this continued up to every 3 months periodically until toceranib ceased.
Toceranib (Palladia; Zoetis, Florham Park, NJ, USA) was administrated at a dose of 2.4 to 2.9 mg/kg which causes sufficient target inhibition and the treatment schedule was on a Monday-Wednesday-Friday basis in most dogs. In some cases, the dose and schedule were adjusted depending on patient’s condition [20]. In the case of symptoms of toxicity (lethargy, weight loss, inappetence, diarrhea, vomiting, fever, syncope), toceranib was discontinued until side effects improved, and then re-administration began with a dose reduced by 0.5 mg/kg.
Most of dogs (20/31) with surgical removal of tumor burden or biopsy were confirmed by histopathological examination. The surgical margin, mitotic count, and vascular invasion of tumor were evaluated for each malignant tumor according to the histopathology report. Some dogs (11/31) were tentatively diagnosed by cytology based on fine needle aspiration in mostly MCTs (6 of 11). Toceranib was administrated first by the choice of owner who was burdened with surgery or intravenous injection of antitumor drug or by the presence of distant metastasis or to prevent recurrence after surgery. Vinblastine and prednisolone with or without lomustine were used as the first dugs for MCT treatment and replaced or combined with toceranib due to side effects, no treatment response or recurrence of tumor. Also, electrochemotherapy was applied to gross tumor (relapsed or not) with toceranib. At the time of treatment, 10 dogs had other existing underlying diseases.

Response to therapy

The response to therapy was assessed in 31 dogs using diagnostic images (radiographs, US, or CT) and direct measurement of the tumor diameter if possible. The responses of gross (macroscopic) tumors in dogs without surgical intervention or with recurrence of resected tumor were defined as CR (complete regression of the target tumor, no new lesions), PR (partial regression of the target tumor, ≥30% decrease in the longest diameter of the target tumor, no new lesions), progressive disease (PD, > 20% increase in the longest diameter of the target tumor, progression of nontarget lesions and new lesions), or SD (SD, decrease of the target tumor of less than 30% or increase of the target tumors of less than 20%, no progression of nontarget lesions and no new lesions for at least 10 weeks) [21]. The responses of tumors in dogs with microscopic disease after surgical intervention were defined as no evidence of disease (NED, at initiation of treatment, no relapse) or PD (metastasis or recurrence of tumor that has been surgically removed or presence of new lesions).
Progression-free survival (PFS) was defined as the time from the initiation of toceranib to PD or death from any cause. The median survival time (MST) was defined as the time from initiation of toceranib to death from any cause. If the dog was alive at the time of writing this manuscript, the survival time was calculated using the last date recorded in the medical notes.
PFS and MST were assessed in the total population (31 dogs) by reviewing the medical records. Clinical benefit was determined by response to treatment and was defined as CR or PR of any duration, or SD for at least 10 weeks in dogs with gross disease.

Assessment of AEs

All dogs receiving toceranib were evaluated by physical examination, CBC, serum biochemistry, and urinalysis before treatment and then at intervals that gradually increased from 2 weeks to 1 to 3 months if AEs were not found. All AEs were classified by the attending clinician according to the Veterinary Co-operative Oncology Group’s common terminology criteria for AEs (VCOG-CTCAE v1.1) [22]. Multiple selection was allowed for each dog. For gastrointestinal AEs, supportive care included antiemetics, antidiarrheal agents, and gastric protectants. When neutropenia occurred, prophylactic antibiotics were prescribed until the next evaluation.

Statistical analysis

The Kaplan-Meier method was used to examine PFS and MST according to the studied characteristics of the dogs. Median PFS could not be estimated as tumors recurred in nine dogs (29.0%). Therefore, mean PFS was used. Cox regression analysis was performed to determine factors affecting the recurrence of tumor or death after initiation of toceranib treatment. Variables were selected by a backward elimination method. All statistical analyses were performed using IBM SPSS Statistics for Windows, version 25.0 (IBM Corp., USA). A p-value of < 0.05 was considered statistically significant.


Study population

Thirty-one dogs with tumors were treated with toceranib either alone or in combination with metronomic chemotherapy, surgery, or both for the study period. The population included 21 female dogs (18 spayed) and 10 male dogs (8 castrated). Fourteen different breeds were presented (Table 1). The median age was 13 years (range, 6 to 18 years) and the median body weight was 5 kg (range 2.3 to 42 kg). The types of tumor characterized in the study population consisted of epithelial tumors (n = 12), mesenchymal tumors (n = 10), and round cell tumors (n = 9). The majority of the dogs (51.6%) were treated with toceranib in the absence of evidence of mass after surgical resection of a tumor. The remaining dogs (48.4%) were treated in the presence of primary tumor, metastasis, recurrent tumor, or a combination thereof. Metastasis located in distant organs was present in only 3 dogs (9.7%) at initiation of toceranib, but 14 dogs (45.2%) had enlarged LNs around the target tumor. Detailed patient characteristics are presented in Table 2.
Overview table with following information for each dog enrolled in the study was described in the supplement.


The median dose of toceranib used in treated dogs was 2.5 mg/kg (range, 2.2 to 3 mg/kg). Most dogs (87.1%, 27/31) were administered toceranib three days per week (Monday-Wednesday-Friday), but one dog was administered toceranib every second day and three dogs two days per week (Monday-Thursday).
Nineteen dogs (61.3%) underwent surgery before initiation of treatment. In four of these dogs, regional enlarged LNs removed during surgery were confirmed to have metastases by histopathology. An additional ten dogs had regional enlarged LNs suspected to have metastases after CT or US. Three dogs (9.7%) had distant metastasis of lungs or abdominal carcinomatosis. Histopathologic details such as margin and mitotic count were well characterized (Table 3). There was no vascular invasion of tumor in any of the dogs examined.
Of the 31 dogs in the study population, 21 were treated solely with toceranib and 10 were treated with other chemotherapies during toceranib treatment. Other chemotherapy agents included electrochemotherapy with bleomycin (0.3 mg/kg), intratumor injection (n = 3; SCC, intraperitoneal liposarcoma, MCT), vinblastine (n = 3; MCTs), carboplatin (n = 1; SCC), prednisolone (n = 5; four MCT, one MGT), and non-steroidal anti-inflammatory drugs (n = 2; SCC, MGT).

Treatment outcome

Clinical benefit was observed in 13 of 15 dogs (86.7%; 3 with CR, 4 with PR, 6 with SD) with gross disease. The remaining two dogs (13.3%) had PD (Table 3). Of the 13 dogs for which toceranib treatment showed benefit, 11 presented prolonged clinical benefit (median 35 days; range, 7 to 490 days) from cessation of toceranib to death or last date reported. 2 dogs in these groups were expired during toceranib treatment; 1 had PR, which then turned to PD, and 1 with SD died due to deterioration from toceranib-related side effects. The 16 dogs (51.6%) with microscopic disease were defined as having NED at the initiation of toceranib treatment. Seven dogs with NED had PD during toceranib treatment or after discontinuation of toceranib.
In the 31 treated dogs, the toceranib-related mean PFS and median MST were 471 and 199 days, respectively, based on the Kaplan-Meier product of survival time (Fig. 1). Distant metastasis was significantly associated with PFS (p < 0.05). Response to treatment and treatment setting (macro- or micro-scopic) were significantly associated with MST (p < 0.001 and p < 0.05, respectively). The median MSTs for dogs with CR, PR, SD, and PD were 311, 133, 187, and 156 days, respectively. The mean PFS and median MST were 440 and 290 days, respectively, for dogs that underwent surgery and 450 and 154 days, respectively, for dogs that did not undergo surgery. The mean PFS and median MST were 315 and 199 days, respectively, for dogs with mesenchymal tumors, 588 and 311 days, respectively, for dogs with epithelial tumors, and 421 and 156 days, respectively, for dogs with round cell tumors. The mean PFS and median MST were 410 and 290 days, respectively, for dogs with microscopic disease, compared with 463 and 169 days, respectively, for dogs with gross disease. The mean PFS and median MST were 389 and 169 days, respectively, for dogs that received multiple chemotherapeutic drugs, compared with 463 and 289 days, respectively, for dogs that received toceranib alone. The mean PFS and median MST were 90 and 187 days, respectively, for dogs with distant metastasis, compared with 493 and 220 days, respectively, for dogs with no distant metastasis. The mean PFS and median MST were 224 and 169 days, respectively, for dogs with regional enlarged LNs, compared with 553 and 289 days, respectively, for dogs which did not have regional enlarged LNs. The mean PFS and median MST were 425 and 187 days, respectively, for dogs with underlying disease, compared with 413 and 289 days, respectively, for dogs without underlying disease. The mean PFS and median MST were 469 and 289 days, respectively, for dogs with symptoms of toxicity to toceranib, compared with 388 and 199 days, respectively, for dogs without toxicity to toceranib (Table 4).

Prognostic factors

Multiple factors were assessed for their influence on prognosis using a multivariable Cox proportional hazard model for PFS (Table 5) and MST (Table 6). Multiple chemotherapy and distant metastasis (in PFS) and surgery, regional enlarged LN, underlying disease, and toxicity (in MST) negatively affected prognosis. Conversely, epithelial and round cell tumors and duration of toceranib (in PFS) and epithelial tumors, microscopic disease, NED, SD, and duration of toceranib (in MST) positively affected prognosis.
In dogs that underwent surgery, none of the examined factors were significantly associated with MST (Table 7).

Adverse events

AEs occurred in 14/31 (45.2%) of the dogs treated with toceranib. The categories, grades (1 to 3), and incidence rate per category of these AEs are described in Table 8. There were no grade 4 or 5 AEs observed in any dogs. The majority of the AEs was grade 1 (54.0%) and categorized as biochemical (39.7%) or gastrointestinal (28.6%) AEs. Most of the gastrointestinal AEs (8/14) were classified as low grade (grades 1 to 2) and were managed quickly by supportive therapy with discontinuation of toceranib. In 6/14 (42.9%) dogs, toceranib administration was discontinued due to AEs (3 biochemical: increased blood urea nitrogen and creatinine; 2 hematologic: 1 neutropenia and 1 anemia; 1 gastrointestinal).


This retrospective study describes the responses of toceranib treatment to various tumors, which has been reported for the first time in republic of Korea. The biological effect of toceranib on various types of tumors was evaluated in mostly small breed dogs. Most of the treated dogs with gross disease (48.4% of the total cohort) presented with clinical benefit (86.7%). This treatment response is consistent with previous studies [10,11,18]. Most previous reports tested the effect of toceranib on one type of tumor while our study supports the use of toceranib in various types of tumor. There have been few studies of the relationship between tumor type and prognosis, but our study shows that epithelial tumors have a low recurrence rate and a high survival rate. In the previous studies assessing toceranib, clinical benefits have mainly been shown in epithelial tumors (‘-carcinoma’) and MCTs [1,6,10,11,13,14,18]. Conversely, few studies have reported effects on mesenchymal tumors such as GIST, OSA, injection site sarcoma, and histiocytic sarcoma, and these studies were limited by small populations [11,18,23-25]. Mutations in c-KIT, an important factor which is the target of small-molecule tyrosine kinase inhibitors in veterinary medicine, have been found in MCTs (grades 1 to 3) in dogs, and in GIST and mammary gland tumor (grades 2 to 3) in dogs and humans [15,26-28]. In our study, dogs with epithelial tumors with sufficient clinical evidence had the highest representation (12 of 31 dogs, 38.7%) and showed clinical benefit from toceranib treatment, including two dogs with CR.
Using a Cox regression analysis, we identified that NED or SD response to treatment had a significantly positive effect on prognosis (in MST). Unexpectedly, CR and PR did not have a significant effect on prognosis, despite the clinical benefit of toceranib. A previous report showed that PR and SD were positive factors of prognosis [9]. Since our study involved 31 dogs and was limited to three centers, a direct comparison with previous retrospective studies may not be appropriate. However, the following points may explain why the effect of PR on prognosis found in our study differed from that in other studies. In our study, a total of four dogs (one with SCC, and three with MCT, stage 3) that experienced PR all died of each tumor, and their median MST was 133 days. Of these, the first responded to secondary toceranib treatment after several trials with other chemotherapies, but had recurrence two weeks before death and the patient’s condition was deteriorated quickly. The second dog also experienced recurrence two weeks before death from a distant metastasis (carcinomatosis). The third dog initially showed PR, but the tumor continued to increase, and leading to PD. The fourth was already in a state of relapse after surgery when toceranib was initiated. Therefore, the dogs that experienced PR all showed rapid relapse and deterioration of patient’s condition even though a clinical benefit from the treatment was recorded. Overall, the fact that our study had conditions differing from the earlier report needs to be fully considered and interpreted.
In our study, dogs that underwent surgery had a worse prognosis than those that did not, and dogs with microscopic disease had a better prognosis than those without. In a previous report, the effect of surgery on prognosis was not statistically significant [10]. In our study, of the dogs that underwent surgery, 16/19 initiated toceranib treatment in a microscopic disease setting and recurrence occurred in three dogs after surgery, resulting in gross disease (3/19). Considering the result that the microscopic condition had a significant positive effect on the prognosis, these dogs relapsed after surgery had poor MST, even if clinical benefit (two with CR and one with PR) was observed. So, surgery was considered a negative factor of prognosis in our study.
In dogs with regional enlarged LN and distant metastasis, the prognosis (MST) was poor. Previous studies have shown results consistent with this finding [10,17,18,29]. Conversely, in one report related to grade 2 MCTs, the survival time between dogs with and without regional LN metastasis was no significant difference. However, prolonged survival time was observed in dogs in which metastatic LNs were removed [30]. Our study identified regional enlarged LN was removed in only 4 of 14 dogs.
The median dose of toceranib used in treated dogs was 2.5 mg/kg (range, 2.2 to 3 mg/kg). According to existing reports, low doses of 2.5 to 2.9 mg/kg every other day are well tolerated without grade 3 or 4 AEs, compared with dosing at 3.25 mg/kg every other day [20]. In our study, 10 dogs had existing underlying diseases (three with heart failure, one with chronic kidney disease, four with both heart and kidney disease, and two with chronic pancreatitis). Depending on these concomitant diseases, main side effects were occurred and therefore biochemistry AEs was the most common (39.7%), unlikely to another reports. Gastrointestinal AEs were the second most common type of AEs, and these were effectively managed in grades 1 to 2 through drug holidays, supportive medicine, and dose adjustments to avoid drug withdrawal. The dogs that died from severe side effects developed worsening chronic kidney disease, severe pancreatitis, or anemia and did not recover.
There were several limitations of our study. Not only was the overall population size small, but the numbers in the subgroup analyses were also small. These findings should be further confirmed in a large number of small breed dogs. As this study had a retrospective design, it was impossible to match baseline characteristics such as sex, biochemistry, and underlying diseases. Additionally, toceranib affecting the tumor microenvironment (TME) in various tumor types may be assessed by molecular biology in other ways, such as Western blots or immunohistochemistry [31].
In conclusion, a clinical benefit of toceranib treatment was noted in the majority of the 15 dogs with gross disease in our study (86.7%). In the 31 treated dogs, the toceranib-related mean PFS was 471 days and the median MST was 199 days. Complex chemotherapy and distant metastasis (PFS), surgery, regional enlarged LN, underlying disease, and toxicity (MST) were negative prognostic factors. Our results provide additional information about the clinical efficacy of toceranib and suggest that the toceranib is probably selective treatment to various tumor types in small breed dogs. Further study is required to evaluate its clinical activity in a large number of small breed dogs.

Conflict of interest

The authors declare no conflict of interest.


We are thanks to the Cooperative Research Program of Center for Companion Animal Research (Project no. PJ014045022020): Rural Development Administration, Republic of Korea for the support.

Supplementary Materials

Supplementary Table 1.
Overview table with additional information for each dog enrolled in the study (n = 31).
Supplementary Table 2.
Overview table with additional information for each dog enrolled in the study (n = 31).

Fig. 1.
(A) Kaplan-Meier progression free survival curve based on the time of toceranib initiation (mean 471 days, range 370-571); (B) Kaplan-Meier median survival time curve based on the time of toceranib treatment initiation (median 199 days, range 89-309). All censored dogs are marked with a cross.
Table 1.
Summary of breeds included in this study (n = 31)
Breed Number of dogs Percentage (%)
Maltese 8 25.8
Shih Tzu 5 16.1
Mixed 5 16.1
Yorkshire Terrier 2 6.5
Miniature Pinscher 2 6.5
Miniature Schnauzer 1 3.2
Golden Retriever 1 3.2
Labrador Retriever 1 3.2
Welsh Corgi 1 3.2
Bichon Frise 1 3.2
Jindo 1 3.2
Beagle 1 3.2
Poodle 1 3.2
Pug 1 3.2
Table 2.
Patient characteristics and additional tumor information (n = 31)
Parameter Type of tumor
Number of dogs (%)
Epithelial (n = 12) Mesenchymal (n = 10) RCT (n = 9)
 Intact female 2 1 0 3 (9.7)
 Spayed female 8 5 5 18 (58.1)
 Intact male 0 1 1 2 (6.5)
 Castrated male 2 3 3 8 (25.8)
 Yes 9 7 3 19 (61.3)
 No 3 3 6 12 (38.7)
Margin (n = 19)
 Complete* 3 3 0 6 (31.6)
 Incomplete 6 4 3 13 (68.4)
Mitotic figure (n = 19)
 < 10 (/10 high per field) 7 4 2 13 (68.4)
 ≥ 10 (/10 high per field) 2 3 1 6 (31.6)
Disease setting
 Gross 5 3 7 15 (48.4)
 Micro 7 7 2 16 (51.6)
Distant metastasis
 Present 0 2 1 3 (9.7)
 Absent 12 8 8 28 (90.3)
Regional enlarged LN
 Yes 6 3 5 14 (45.2)
 No 6 7 4 17 (54.8)
 Sole 9 8 4 21 (67.7)
 Multiple§ 3 2 5 10 (32.3)
Underlying disease
 Yes 5 2 3 10 (32.3)
 No 7 8 6 21 (67.7)

RCT, round cell tumor; LN, lymph node.

* Complete margin was defined by the histopathology report.

Metastasis includes regional lymph nodes or lungs, confirmed by histopathology and computed tomography.

Enlarged lymph nodes (mesenteric, superficial etc.) suspected of metastasis were detected around the tumor.

§ Multiple chemotherapy means using not only toceranib but also prednisolone, non-steroidal anti-inflammatories, or other medication.

Table 3.
Clinical benefits of toceranib administration in 15 dogs with gross disease
Clinical benefit
No clinical benefit
CR PR SD, greater than 10 weeks SD, less than 10 weeks PD
All dogs with gross disease (n = 15) 3 4 6 0 2
Disease setting at treatment initiation
 Primary gross disease (n = 12) 1 3 6 0 2
 Recurrence after surgery (n = 3) 2 1 0 0 0

CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.

Table 4.
Progression-free survival (PFS) and median survival time (MST) based on the Kaplan-Meier method
Variable Number of dogs Kaplan-Meier method (d)
Mean SE 95% CI Median SE 95% CI
Total 31 470.8 51.3 (370.3, 571.3) 199.0 56.3 (88.6, 309.4)
 F/SF 21 417.7 46.3 (326.9, 508.4) 220.0 69.1 (84.5, 355.5)
 M/CM 10 417.8 91.2 (239.1, 596.6) 187.0 34.0 (120.4, 253.6)
 Yes 19 439.7 64.1 (314.0, 565.4) 290.0 56.9 (178.5, 401.5)
 No 12 450.1 49.1 (353.8, 546.4) 154.0 23.0 (109.0, 199.0)
Type of tumor
 Mesenchymal 10 315.4 63.6 (190.8, 439.9) 199.0 6.0 (187.3, 210.7)
 Epithelial 12 558.7 62.7 (435.8, 681.7) 311.0 132.8 (50.7, 571.3)
 RCT 9 420.8 65.6 (292.1, 549.4) 156.0 22.4 (112.2, 199.8)
Tx setting
 Micro 16 410.0 69.3 (274.2, 545.8) 290.0 64.3 (163.9, 416.1)
 Gross 15 463.1 41.4 (382.0, 544.2) 169.0 25.7 (118.6, 219.4)
Tx response
 PD 9 - - - 156.0 23.7 (109.5, 202.5)
 SD 6 - - - 187.0 36.1 (116.1, 257.9)
 PR 4 - - - 133.0 32.0 (70.3, 195.7)
 CR 3 - - - 311.0 - -
 NED 9 - - - 656.0 0.0 -
 Multiple 10 388.6 66.5 (258.3, 518.9) 169.0 45.0 (80.8, 257.2)
 Sole 21 463.2 63.9 (337.9, 588.4) 289.0 81.1 (130.1, 447.9)
Distant metastasis
 Yes 3 90.3 39.5 (13.0, 167.7) 187.0 0.0 -
 No 28 493.0 52.4 (390.2, 595.7) 220.0 65.4 (91.8, 348.2)
Regional enlarged LN
 Yes 14 224.1 39.0 (147.7, 300.6) 169.0 11.0 (147.5, 190.5)
 No 17 552.6 53.5 (447.7, 657.6) 289.0 57.9 (175.5, 402.5)
Underlying disease
 Yes 10 424.5 90.1 (247.9, 601.1) 187.0 39.5 (109.5, 264.5)
 No 21 412.8 47.7 (319.3, 506.4) 289.0 54.9 (181.4, 396.6)
 Yes 14 469.1 45.4 (380.1, 558.2) 289.0 73.3 (145.4, 432.6)
 No 17 388.4 74.6 (242.1, 534.7) 199.0 51.3 (98.5, 299.5)

SE, standard error; CI, confidence interval; F, female; SF, spayed female; M, male; CM, castrated male; RCT, round cell tumor; Tx, treatment; PD, progressive disease; SD, stable disease; PR, partial response; CR, complete response; NED, no evidence of disease; LN, lymph node.

* Median PFS could not be estimated as nine dogs (29.0%) had tumor recurrence. Therefore, mean PFS was used.

Table 5.
Prognostic factors based on Cox proportional hazard model for progression-free survival (PFS)
Variable PFS
HR 95% CI p-value
Surgery 69.06 (0.86, 5,560.44) 0.06
Type of tumor
 Epithelial 0.02 (0.00, 0.68) 0.03*
 RCT 0.01 (0.00, 0.61) 0.03*
Chemotherapy 42.66 (1.83, 991.88) 0.02*
Distant metastasis 663.52 (2.87, 153,515.22) 0.02*
Regional enlarged LN 4.88 (0.48, 49.67) 0.18
Duration of administration 0.97 (0.95, 1.00) 0.02*
Toxicity 0.11 (0.01, 2.03) 0.14

HR, hazard ratio; CI, confidence interval; RCT, round cell tumor; LN, lymph node.

Reference category: surgery (no = 0), type of tumor (mesenchymal = 0), chemotherapy (sole = 0), distant metastasis (no = 0), regional enlarged LN (no = 0), toxicity (no = 0).

* p < 0.05.

Table 6.
Prognostic factors based on Cox proportional hazard model for median survival time (MST)
Variable MST
HR 95% CI p-value
Surgery 91.62 (1.17, 7,149.10) 0.04*
Type of tumor
 Epithelial 0.02 (0.00, 0.62) 0.03*
 RCT 0.30 (0.02, 3.50) 0.33
Tx setting 0.00 (0.00, 0.05) < 0.01**
Tx response
 SD 0.00 (0.00, 0.05) < 0.01**
 PR 0.09 (0.00, 3.18) 0.19
 CR 0.00 (0.00, 1.91) 0.07
 NED 0.02 (0.00, 0.41) 0.01*
Regional enlarged LN 6.86 (1.05, 44.87) 0.04*
Duration of administration 0.97 (0.95, 1.00) 0.03*
Underlying disease 17.27 (2.00, 149.06) < 0.01**
Toxicity 22.07 (1.85, 263.21) 0.01*

HR, hazard ratio; CI, confidence interval; RCT, round cell tumor; Tx, treatment; SD, stable disease; PR, partial response; CR, complete response; NED, no evidence of disease; LN, lymph node; PD, progressive disease.

Reference category: surgery (no = 0), type of tumor (mesenchymal = 0), Tx setting (gross = 0), Tx response (PD = 0), Regional enlarged LN (no = 0), underlying disease (no = 0), toxicity (no = 0).

* p < 0.05,

** p < 0.01.

Table 7.
Prognostic factors based on Cox proportional hazard model for median survival time (MST) in the group that underwent surgery
Variable* MST
HR 95% CI p-value
Mitotic count 1.02 (0.98, 1.07) 0.33
Margin 0.20 (0.02, 2.26) 0.19
Distant metastasis 0.00 (0.00, -) 0.99
Regional enlarged LN 2.01 (0.35, 11.46) 0.43

HR, hazard ratio; CI, confidence interval; LN, lymph node.

* Reference category: margin count (incomplete = 0), distant metastasis (no = 0), regional enlarged LN (no = 0).

Table 8.
Adverse events (AEs) in dogs treated with toceranib (45.2% of the total study cohort)
Category Term Number*
Incidence rate
Grade 1 Grade 2 Grade 3 (% in dogs with observed AEs)
Constitutional Lethargy 1 2 . 6.3 (3.1)
Weight loss 1 . .
Gastrointestinal Inappetence 2 3 1 28.6 (12.9)
Diarrhea 2 3 .
Vomiting 2 2 .
Hematologic Neutropenia 6 1 . 20.6 (9.3)
Lymphopenia . . .
Anemia 5 1 .
Biochemical Increased ALT activity 2 2 1 39.7 (17.9)
Increased ALP activity 1 2 2
Increased BUN 4 . 3
Increased Creatinine 4 3 1
Renal Proteinuria 1 . 1 3.2 (1.4)
Cardiovascular Syncope . . 1 3.2 (1.4)
Hypertension 1 . .
Dermatologic Alopecia 1 . . 3.2 (1.4)
Hyperpigmentation 1 . .
Total (number) 34 19 10
Total (%) 54.0 30.2 15.8 100.0 (45.2)

ALT, alanine aminotransferase; ALP, alkaline phosphatase; BUN, blood urea nitrogen.

* Number includes overlap selection.

Incidence rate was defined as percentage of occurrence on the category among all adverse events and after that percentage in the brackets indicates occurrence on dogs in which AEs were observed.


1. Pryer NK, Lee LB, Zadovaskaya R, Yu X, Sukbuntherng J, Cherrington JM, London CA. Proof of target for SU11654: inhibition of KIT phosphorylation in canine mast cell tumors. Clin Cancer Res 2003;9:5729-5734.
2. Chow LQ, Eckhardt SG. Sunitinib: from rational design to clinical efficacy. J Clin Oncol 2007;25:884-896.
crossref pmid
3. Papaetis GS, Syrigos KN. Sunitinib: a multitargeted receptor tyrosine kinase inhibitor in the era of molecular cancer therapies. BioDrugs 2009;23:377-389.
4. Vail DM, Thamm DH, Liptak JM. Withrow and MacEwen’s Small Animal Clinical Oncology. 6th ed. pp. 197-198, Elsevier, St. Louis, 2020.
5. London CA, Hannah AL, Zadovoskaya R, Chien MB, Kollias-Baker C, Rosenberg M, Downing S, Post G, Boucher J, Shenoy N, Mendel DB, McMahon G, Cherrington JM. Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies. Clin Cancer Res 2003;9:2755-2768.
6. London CA, Malpas PB, Wood-Follis SL, Boucher JF, Rusk AW, Rosenberg MP, Henry CJ, Mitchener KL, Klein MK, Hintermeister JG, Bergman PJ, Couto GC, Mauldin GN, Michels GM. Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision. Clin Cancer Res 2009;15:3856-3865.
crossref pmid
7. Shin HR, Kim JS, Kim SM, Song KH, Seo KW. Metronomic chemotherapy with toceranib phosphate for treatment of a chemodectoma in a dog. J Vet Clin 2017;34:43-46.
8. Musser ML, Taikowski KL, Johannes CM, Bergman PJ. Retrospective evaluation of toceranib phosphate (Palladia®) use in the treatment of inoperable, metastatic, or recurrent canine pheochromocytomas: 5 dogs (2014-2017). BMC Vet Res 2018;14:272.
crossref pmid pmc
9. Koshino A, Mauldin GE, Dickinson RM, Mauldin GN. A clinical oncology case report. Can Vet J 2011;52:899-902.
pmid pmc
10. Heaton CM, Fernandes AFA, Jark PC, Pan X. Evaluation of toceranib for treatment of apocrine gland anal sac adenocarcinoma in dogs. J Vet Intern Med 2020;34:873-881.
crossref pmid pmc
11. London C, Mathie T, Stingle N, Clifford C, Haney S, Klein MK, Beaver L, Vickery K, Vail DM, Hershey B, Ettinger S, Vaughan A, Alvarez F, Hillman L, Kiselow M, Thamm D, Higginbotham ML, Gauthier M, Krick E, Phillips B, Ladue T, Jones P, Bryan J, Gill V, Novasad A, Fulton L, Carreras J, McNeill C, Henry C, Gillings S. Preliminary evidence for biologic activity of toceranib phosphate (Palladia(®)) in solid tumours. Vet Comp Oncol 2012;10:194-205.
crossref pmid
12. de Vos J, Ramos Vega S, Noorman E, de Vos P. Primary frontal sinus squamous cell carcinoma in three dogs treated with piroxicam combined with carboplatin or toceranib. Vet Comp Oncol 2012;10:206-213.
crossref pmid
13. Heishima K, Iwasaki R, Kawabe M, Murakami M, Sakai H, Maruo K, Mori T. Short-term administration of single-agent toceranib in six cases of inoperable massive canine hepatocellular carcinoma. J Am Anim Hosp Assoc 2019;55:35-41.
14. Sheppard-Olivares S, Bello NM, Wood E, Szivek A, Biller B, Hocker S, Wouda RM. Toceranib phosphate in the treatment of canine thyroid carcinoma: 42 cases (2009-2018). Vet Comp Oncol 2020;18:519-527.
crossref pmid
15. Koltai Z, Szabó B, Jakus J, Vajdovich P. Tyrosine kinase expression analyses in canine mammary gland tumours: a pilot study. Acta Vet Hung 2018;66:294-308.
crossref pmid
16. Laver T, London CA, Vail DM, Biller BJ, Coy J, Thamm DH. Prospective evaluation of toceranib phosphate in metastatic canine osteosarcoma. Vet Comp Oncol 2018;16:E23-E29.
crossref pmid
17. Kim C, Matsuyama A, Mutsaers AJ, Woods JP. Retrospective evaluation of toceranib (Palladia) treatment for canine metastatic appendicular osteosarcoma. Can Vet J 2017;58:1059-1064.
pmid pmc
18. Berger EP, Johannes CM, Jergens AE, Allenspach K, Powers BE, Du Y, Mochel JP, Fox LE, Musser ML. Retrospective evaluation of toceranib phosphate (Palladia®) use in the treatment of gastrointestinal stromal tumors of dogs. J Vet Intern Med 2018;32:2045-2053.
crossref pmid pmc
19. Yamazaki H, Miura N, Lai YC, Takahashi M, Goto-Koshino Y, Yasuyuki M, Nakaichi M, Tsujimoto H, Setoguchi A, Endo Y. Effects of toceranib phosphate (Palladia) monotherapy on multidrug resistant lymphoma in dogs. J Vet Med Sci 2017;79:1225-1229.
crossref pmid pmc
20. Bernabe LF, Portela R, Nguyen S, Kisseberth WC, Pennell M, Yancey MF, London CA. Evaluation of the adverse event profile and pharmacodynamics of toceranib phosphate administered to dogs with solid tumors at doses below the maximum tolerated dose. BMC Vet Res 2013;9:190.
crossref pmid pmc
21. Nguyen SM, Thamm DH, Vail DM, London CA. Response evaluation criteria for solid tumours in dogs (v1.0): a Veterinary Cooperative Oncology Group (VCOG) consensus document. Vet Comp Oncol 2015;13:176-183.
crossref pmid
22. Veterinary Cooperative Oncology Group-Common Terminology Criteria for Adverse Events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.1. Vet Comp Oncol 2016;14:417-446.
23. Elliott JW, Swinbourne F, Parry A, Baines L. Successful treatment of a metastatic, gastrointestinal stromal tumour in a dog with toceranib phosphate (Palladia). J Small Anim Pract 2017;58:416-418.
crossref pmid
24. Hong H, Lim S, Shin HR, Choi H, Lee H, Song KH, Seo KW. Metronomic chemotherapy with toceranib phosphate for a disseminated histiocytic sarcoma in a Miniature Schnauzer dog. J Vet Clin 2017;34:441-444.
25. Jacobs TM, Poehlmann CE, Kiupel M. Injection-site sarcoma in a dog: clinical and pathological findings. Case Rep Vet Med 2017;2017:6952634.
crossref pmid pmc
26. Frost D, Lasota J, Miettinen M. Gastrointestinal stromal tumors and leiomyomas in the dog: a histopathologic, immunohistochemical, and molecular genetic study of 50 cases. Vet Pathol 2003;40:42-54.
crossref pmid
27. Patruno R, Marech I, Zizzo N, Ammendola M, Nardulli P, Gadaleta C, Introna M, Capriuolo G, Rubini RA, Ribatti D, Gadaleta CD, Ranieri G. c-Kit expression, angiogenesis, and grading in canine mast cell tumour: a unique model to study c-Kit driven human malignancies. Biomed Res Int 2014;2014:730246.
crossref pmid pmc
28. Kubo K, Matsuyama S, Katayama K, Tsutsumi C, Yonezawa K, Shimada T, Kotani T, Sakuma S, Ohashi F, Takamori Y. Frequent expression of the c-kit proto-oncogene in canine malignant mammary tumor. J Vet Med Sci 1998;60:1335-1340.
crossref pmid
29. de Araújo MR, Campos LC, Ferreira E, Cassali GD. Quantitation of the regional lymph node metastatic burden and prognosis in malignant mammary tumors of dogs. J Vet Intern Med 2015;29:1360-1367.
crossref pmid pmc
30. Baginski H, Davis G, Bastian RP. The prognostic value of lymph node metastasis with grade 2 MCTs in dogs: 55 cases (2001-2010). J Am Anim Hosp Assoc 2014;50:89-95.
crossref pmid
31. Yamazaki H, Tanaka T, Mie K, Nishida H, Miura N, Akiyoshi H. Assessment of postoperative adjuvant treatment using toceranib phosphate against adenocarcinoma in dogs. J Vet Intern Med 2020;34:1272-1281.
crossref pmid pmc

Editorial Office
#401-1, 85 Bldg., College of Veterinary Medicine, Seoul National University
1 Gwanak-ro, Gwanak-gu, Seoul 08826, Korea
Tel: +82-2-880-1229    Fax: +82-2-878-9762    E-mail: jvs@ksvs.or.kr                

Copyright © 2021 by The Korean Society of Veterinary Science.

Developed in M2PI

Close layer
prev next